Biotech · Private company
Xenon Pharmaceuticals Inc.
Track this companyFree. Adds Xenon Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials139 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- AzetukalnerPhase 3 · Bipolar DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AzetukalnerPhase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AzetukalnerPhase 3 · Bipolar DepressionClinicalTrials.gov · fetched Nov 12, 2026
- XEN1101Phase 3 · Focal Onset SeizuresClinicalTrials.gov · fetched Nov 12, 2026
- XEN1101Phase 3 · Primary Generalized Tonic-Clonic SeizuresClinicalTrials.gov · fetched Nov 12, 2026
- XEN1101Phase 3 · Focal EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- XEN496Phase 3 · EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- XEN1101 10 mgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- XEN1101 20 mgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 30, 2025ClinicalTrials.gov NCT07217860 · fetched Nov 12, 2026
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 8, 2025ClinicalTrials.gov NCT07172516 · fetched Nov 12, 2026
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 8, 2025ClinicalTrials.gov NCT07076407 · fetched Nov 12, 2026
- An Open-Label Study of Azetukalner in Major Depressive DisorderPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 18, 2025ClinicalTrials.gov NCT06922110 · fetched Nov 12, 2026
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 20, 2024ClinicalTrials.gov NCT06775379 · fetched Nov 12, 2026
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)PHASE3 · RECRUITING · started May 9, 2023ClinicalTrials.gov NCT05716100 · fetched Nov 12, 2026
- An Open-label Study of XEN1101 in EpilepsyPHASE3 · ENROLLING_BY_INVITATION · started Apr 25, 2023ClinicalTrials.gov NCT05718817 · fetched Nov 12, 2026
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPHASE3 · RECRUITING · started Feb 14, 2023ClinicalTrials.gov NCT05667142 · fetched Nov 12, 2026
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresPHASE3 · COMPLETED · started Nov 18, 2022ClinicalTrials.gov NCT05614063 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderPHASE2 · COMPLETED · started May 19, 2022ClinicalTrials.gov NCT05376150 · fetched Nov 12, 2026
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEEPHASE3 · TERMINATED · started Aug 17, 2021ClinicalTrials.gov NCT04912856 · fetched Nov 12, 2026
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyPHASE3 · TERMINATED · started Mar 29, 2021ClinicalTrials.gov NCT04639310 · fetched Nov 12, 2026
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2019ClinicalTrials.gov NCT03796962 · fetched Nov 12, 2026